282 related articles for article (PubMed ID: 17237677)
1. Antiangiogenic therapy in neovascular age-related macular degeneration.
Lin RC; Rosenfeld PJ
Int Ophthalmol Clin; 2007; 47(1):117-37. PubMed ID: 17237677
[No Abstract] [Full Text] [Related]
2. Re: Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
Nelson M
Retina; 2010 Feb; 30(2):380; author reply 380-1. PubMed ID: 20142719
[No Abstract] [Full Text] [Related]
3. [Antiangiogenic therapy].
Arias Barquet L
Arch Soc Esp Oftalmol; 2005 Aug; 80(8):435-6. PubMed ID: 16136393
[No Abstract] [Full Text] [Related]
4. Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
Shah GK; Sang DN; Hughes MS
Retina; 2009 Feb; 29(2):133-48. PubMed ID: 19202423
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration.
Aggio FB; Melo GB; Höfling-Lima AL; Eid Farah M
Acta Ophthalmol Scand; 2006 Dec; 84(6):831-3. PubMed ID: 17083553
[No Abstract] [Full Text] [Related]
6. Ranibizumab and nonocular hemorrhage.
Beaumont PE; Kang HK
Ophthalmology; 2009 Aug; 116(8):1593. PubMed ID: 19651322
[No Abstract] [Full Text] [Related]
7. A cost-effectiveness analysis of three treatments for age-related macular degeneration.
Gower EW; Cassard SD; Bass EB; Schein OD; Bressler NM
Retina; 2010 Feb; 30(2):212-21. PubMed ID: 19940805
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
[TBL] [Abstract][Full Text] [Related]
9. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.
Kaiser PK; Brown DM; Zhang K; Hudson HL; Holz FG; Shapiro H; Schneider S; Acharya NR
Am J Ophthalmol; 2007 Dec; 144(6):850-857. PubMed ID: 17949673
[TBL] [Abstract][Full Text] [Related]
10. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
Kourlas H; Abrams P
Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
[TBL] [Abstract][Full Text] [Related]
11. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.
Heier JS; Boyer DS; Ciulla TA; Ferrone PJ; Jumper JM; Gentile RC; Kotlovker D; Chung CY; Kim RY;
Arch Ophthalmol; 2006 Nov; 124(11):1532-42. PubMed ID: 17101999
[TBL] [Abstract][Full Text] [Related]
12. Correspondence.
Uparkar M; Maiti A; Natarajan S
Retina; 2008 Mar; 28(3):527; author reply 527-8. PubMed ID: 18327151
[No Abstract] [Full Text] [Related]
13. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.
Antoszyk AN; Tuomi L; Chung CY; Singh A;
Am J Ophthalmol; 2008 May; 145(5):862-74. PubMed ID: 18321465
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with verteporfin and anti-VEGF agents in neovascular age-related macular degeneration: where do we stand?
Kaiser PK
Br J Ophthalmol; 2010 Feb; 94(2):143-5. PubMed ID: 20139287
[No Abstract] [Full Text] [Related]
15. Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed.
Farah SE
Ophthalmic Surg Lasers Imaging; 2008; 39(4):294-8. PubMed ID: 18717434
[TBL] [Abstract][Full Text] [Related]
16. [Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration].
Klin Monbl Augenheilkd; 2007 Jul; 224(7):559-66. PubMed ID: 17657689
[TBL] [Abstract][Full Text] [Related]
17. Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
Brown DM; Kaiser PK; Michels M; Soubrane G; Heier JS; Kim RY; Sy JP; Schneider S;
N Engl J Med; 2006 Oct; 355(14):1432-44. PubMed ID: 17021319
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of neovascular age-related macular degeneration with antiangiogenic drugs].
Rodrigues EB; Rossi EE; Grumann Junior A; Meyer CH; Ho AC
Arq Bras Oftalmol; 2006; 69(5):756-65. PubMed ID: 17187150
[TBL] [Abstract][Full Text] [Related]
19. Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Ziemssen F; Heiduschka P; Schraermeyer U;
Retina; 2007 Oct; 27(8):1154-6; author reply 1156-8. PubMed ID: 18040264
[No Abstract] [Full Text] [Related]
20. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
Retina; 2006; 26(9):988-93. PubMed ID: 17151484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
